Announcement under Regulation 30 of Listing Regulations,2015 for Earning Conference call Transcript.

August 05, 2026 Ref:- GHL/2026-27/EXCH/39 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Code: 543654 Symbol: MEDANTA Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Earnings Conference Call Transcript Dear Sir(s), Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the transcript of Earnings Conference Call held on Friday, July 31, 2026, for the First Quarter ended June 30, 2026 results. The Transcript is also available at our website: https://www.medanta.org/investor-relation This is for your information and record. For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M. No. A17035 Encl: a/a Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 “Global Health Limited – Medanta Q1 FY27 Earnings Conference Call” July 31, 2026 MANAGEMENT: DR. NARESH TREHAN – CHAIRMAN AND MANAGING DIRECTOR – GLOBAL HEALTH LIMITED – MEDANTA MR. PANKAJ SAHNI – GROUP CHIEF EXECUTIVE OFFICER AND DIRECTOR – GLOBAL HEALTH LIMITED – MEDANTA MR. YOGESH KUMAR GUPTA – CHIEF FINANCIAL OFFICER – GLOBAL HEALTH LIMITED – MEDANTA MR. GAURAV CHUGH – HEAD INVESTOR RELATIONS – GLOBAL HEALTH LIMITED – MEDANTA MODERATOR: MR. AMEY CHALKE – JM FINANCIAL INSTITUTIONAL SECURITIES Page 1 of 18 Global Health Limited – Medanta July 31, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Medanta Global Health Q1 FY27 Earnings Conference Call hosted by JM Financial Institutional Securities. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Amey Chalke from JM Financial Institutional Securities. Thank you, and over to you, sir. Amey Chalke: Thank you. Good afternoon, and warm welcome to all the participants on Global Health Limited 1Q FY27 Earnings Call hosted by JM Financial. Today on this call, we have with us from the management, Dr. Naresh Trehan, Chairman and Managing Director; Mr. Pankaj Sahni, Group CEO and Director; Mr. Yogesh Kumar Gupta, Chief Financial Officer; and Mr. Gaurav Chugh, Head of Investor Relations. I will now hand over the call to Dr. Trehan for his opening remarks. Thank you, and over to you Doctor. Naresh Trehan: Thank you for this opportunity. Good afternoon to all of you. Thank you for joining us today on Medanta's Q1 FY27 Earnings Conference Call. I hope you all have had the chance to review the results and presentations that were released yesterday. At Medanta, we continue to build on our vision of delivering world-class, patient-centric and compassionate care. Clinical excellence remains the cornerstone of our identity. And during the quarter, we remain focused on strengthening that foundation through consistent and disciplined execution. The quarter has been encouraging from both a clinical and operational standpoint. Our network continued to witness healthy growth in patient volumes, driven by increasing demand across key specialties, higher case complexity and sustained trust from patients and referring physicians. We also continue to strengthen our position as a destination for complex care through investments in advanced technologies, multidisciplinary programs and world-class clinical talent. I would like to highlight that our Medanta Lucknow has done over 1,000 joint replacements using the latest robotic technology. And that comes on top of thousands of robotic surgeries that we have executed across the system in every specialty, including the more complex cardiac and other specialties. Page 2 of 18 Global Health Limited – Medanta July 31, 2026 Talent remains core to our delivery model. During the quarter, we onboarded over 70 doctors, including 50-plus senior clinicians across specialties. This strengthens our medical depth and enhances our ability to manage complex multidisciplinary care. As we grow, we remain focused not just on scale, but on creating meaningful measurable impact by enhancing access to advanced health care, nurturing clinical leadership and continue to lead through innovation. Based on this philosophy, we have scaled up our plans for Guwahati, which will now have 650-bed super specialty hospital. Our objective is to improve access to advanced tertiary and quaternary health care for patients across the Northeast, where significant demand currently travels outside the region for complex treatment. With a resilient business model, deep medical expertise and a purpose-driven culture, we believe we have the right building blocks in place to carry this momentum forward to touch more lives, serve more communities and set new benchmarks in quality care. Overall, we are pleased with the progress during the quarter and remain confident in our long-term growth strategy. With that, let me now hand over the call to Mr. Pankaj Sahni, our Group CEO, who will walk you through the strategic, operational and financial highlights for the quarter. Thank you all of you for your participation. Over to you, Pankaj. Pankaj Sahni: Thank you, Dr. Trehan. Good afternoon, and thank you for joining us today. FY27 has begun on a strong note for Medanta. In quarter 1 FY27, we delivered robust growth in our total income and EBITDA, reflecting the strength of our operating platform and disciplined execution across the network. The growth was broad-based, driven by robust patient volumes, improved realization, continued scaling of Medanta Noida and sustained momentum across our established hospitals. Let me first take you through our financial performance highlights for Q1 FY27. Consolidated income for the quarter was INR13,262 million, representing a healthy growth of 26% year-on- year. EBITDA, excluding Noida, witnessed a growth of 24% year-on-year to INR3,201 million, with margins improving to 25.8%, highlighting the continued strength of our core operating portfolio. Reported EBITDA, including Noida stood at INR3,153 million, registering a healthy 23% year- on-year growth with EBITDA margins of 23.8%. Below EBITDA, the year-on-year comparison also reflects higher depreciation and finance costs associated with our expanded asset base, particularly following the commissioning and ramping up of Noida. Profit after tax was INR1,573 million compared to INR1,590 million in Q1 FY26. As highlighted in our results, the year-on-year profit after tax was impacted by a nonrecurring exceptional income of INR196 million recognized in Q1 FY26 relating to the reversal of potential interest liability on EPCG, subsequent to the successful merger of our 100% subsidiary, Page 3 of 18 Global Health Limited – Medanta July 31, 2026 MHPL, with GHL. Excluding this onetime item, our underlying earnings trajectory continues to remain very healthy. Operationally, we continue to witness robust momentum across the network. Inpatient volumes increased by 28% year-on-year, while outpatient volumes grew by 34%, reflecting sustained demand across our specialties and the continued scale-up of our new facilities. Occupied bed days for the quarter increased by 21% with network occupancy remaining healthy at 63% on expanded bed capacity. Excluding Noida, occupancy across the network stood at approximately 66%, demonstrating the robust utilization levels across our existing hospitals. Average revenue per occupied bed or ARPOB grew by 5% year-on-year to INR70,244, supported by favorable case mix, [Showing first 8,000 characters — download PDF for full document]